Real ChatGPT answer · index seedE4TMlo3uTlIcompleteHealth and wellness · women's healthinformational
What are the most effective non-hormonal options for menopause symptom relief that target night sweats and mood swings without lowering libido?
Download run
Fan-out diagram
The searches the AI actually ran for this prompt.
SEED QUERY
What are the most effective non-hormonal options for menopause symptom relief that target night sweats and mood swings without lowering libido?
3 real searches · 1 real-search pass
2026 nonhormonal menopause treatment vasomotor symptoms fezolinetant elinzanetant guideline sexual function mood swingsGoogle ↗
OBSERVED
The Menopause Society 2023 nonhormone therapy position statement vasomotor symptoms CBT hypnosis SSRIs gabapentin oxybutynin fezolinetantGoogle ↗
OBSERVED
FDA elinzanetant approval menopause vasomotor symptoms 2025 prescribing informationGoogle ↗
OBSERVED
Badge and edge weight = share of passes that produced the query. Hover a query for its intent and routing format.
Query classes
Google's semantic query class for every sub-query: what kind of answer each search is after, simulated vs real.
Classifying 3 queries…
Searches and sources
ChatGPT3 real searches · gpt-6
2026 nonhormonal menopause treatment vasomotor symptoms fezolinetant elinzanetant guideline sexual function mood swings Google ↗
The Menopause Society 2023 nonhormone therapy position statement vasomotor symptoms CBT hypnosis SSRIs gabapentin oxybutynin fezolinetant Google ↗
FDA elinzanetant approval menopause vasomotor symptoms 2025 prescribing information Google ↗
- These highlights do not include all the information needed to use VEOZAH safely and effectively. See full prescribing information for VEOZAH. VEOZAH® (fezolinetant) tablets, for oral useInitial U.S. Approval: 2023 · dailymed.nlm.nih.gov
- FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause · fda.gov
- Drug Trials Snapshots: LYNKUET · fda.gov
- DailyMed · dailymed.nlm.nih.gov
- label · accessdata.fda.gov
- The 2023 nonhormone therapy position statement of The North American Menopause Society · pubmed.ncbi.nlm.nih.gov
- ACOG Clinical Practice Guideline: Management of... : Obstetrics & Gynecology · doi.org
- ACOG Clinical Practice Guideline: Management of... : Obstetrics & Gynecology · doi.org
- Menopause: The Journal of The North American Menopause Society · menopause.org
Queries
3 queries · click a column to sort
| Query / type | Search | Intent | Query class | Routing format | Cluster | Freq ↓ | Weight |
|---|---|---|---|---|---|---|---|
2026 nonhormonal menopause treatment vasomotor symptoms fezolinetant elinzanetant guideline sexual function mood swings OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 | |
The Menopause Society 2023 nonhormone therapy position statement vasomotor symptoms CBT hypnosis SSRIs gabapentin oxybutynin fezolinetant OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 | |
FDA elinzanetant approval menopause vasomotor symptoms 2025 prescribing information OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 |